KOSDAQ biotech sector Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
13:00
Jul 31
Jul 31
Avoid KOSDAQ secondary battery and biotech stocks
In a leadership-driven market where semiconductors dominate, sector rotation does not occur when the leader falters — the whole index corrects together. KOSDAQ secondary battery and biotech stocks will struggle because the KOSDAQ index remains weak and market interest is focused on the KOSPI leader. Investors should avoid these sectors for now.
MED
01:27
Jul 10
Jul 10
Watch biotech for autumn KOSDAQ leadership
Biotech could become a KOSDAQ star player later this year, especially from autumn when academic conferences resume and potential technology export deals are announced. However, there is currently a catalyst vacuum, so the sector needs to show concrete positive news before becoming a leader. It is worth monitoring for a rotation into biotech.
LOW
01:53
Jun 17
Jun 17
Falling oil benefits Korean biotech
Oil prices have already fallen to the mid-70s and will decline further as Russian, Iranian, and Venezuelan supply comes back online once the Ukraine war ends. Falling oil lowers energy costs and, together with eventually lower interest rates, will revive the KOSDAQ biotech sector which has been neglected during the semiconductor rally.
MED
07:00
Jun 16
Jun 16
Oversold growth sectors to rebound.
Entertainment, gaming, KOSDAQ biotech, and battery stocks have been heavily sold off and are fundamentally cheap. As war fears and rate-hike concerns recede, these previously excluded growth sectors are likely to see a valuation rebound, even if they do not reclaim market leadership. Specific buyback activities (e.g., Pearl Abyss) highlight extreme undervaluation.
MED
11:01
Apr 07
Apr 07
KOSDAQ biotech selling pressure may be ending.
The decline of a major KOSDAQ biotech name forced related biotech ETF selling that dragged the sector, but some bio names such as LigaChem Biosciences and Peptron rose today. The speaker believes the ETF-driven selling pressure may be largely finished, making KOSDAQ biotech a recovery watch if the broader market stabilizes.
MED
01:56
Feb 06
Feb 06
Avoid narrative-driven KOSDAQ batteries and biotech.
Unlike earnings-supported large semiconductors, KOSDAQ secondary battery and biotech names rose mainly on narratives such as humanoid robots and government KOSDAQ support and lack clear earnings visibility. The speaker agrees that falling prices alone may not attract many buyers, making them a lower priority than the large-cap memory names.
MED
03:16
Jan 26
Jan 26
KOSDAQ biotech offers neglected overseas-growth exposure
KOSDAQ biotech names were neglected while KOSPI rose, but their operating profits are improving, overseas big pharma companies continue to call, and the Biosecure Act and broader China-containment measures are creating new offshore contacts and earnings expectations. The speaker therefore sees the KOSDAQ biotech sector as one of the better KOSDAQ areas.
MED
08:30
Jan 25
Jan 25
Korean biotech remains a key overweight.
After earnings season, attention should shift to KOSDAQ and especially biotech. Supply/demand has returned after being washed out, and the speaker plans to increase bio weight. He favors 'real bio' platform companies with genuine technology and concretizing global big pharma collaborations, with the biosecurity law and capacity-expansion themes supporting earnings expectations.
HIGH
08:00
Jan 24
Jan 24
KOSDAQ biotech bottomed; stay involved.
KOSDAQ biotech fell too much on noise even though record licensing deals and partnerships continue, and it has rebounded from a meaningful bottom. It remains a growth industry with government support; investors should stay involved even without buying the exact bottom and increase bio allocation once a clear new leader emerges.
HIGH
11:00
Jan 20
Jan 20
Bio may start after Samsung earnings.
Korean bio is not moving yet, but strong bio names with committed holders are refusing to fall much, and past patterns suggest a bio and KOSDAQ rebound can start after Samsung Electronics' earnings, with JP Morgan healthcare and AAC catalysts giving roughly a month and a half of momentum.
MED
23:30
Jan 10
Jan 10
Buying KOSDAQ biotech patiently for re-rating.
Within KOSDAQ, Lee Young-hoon is specifically buying biotech and advises clients not to be impatient because the sector already moved in November and may feel slow now. He expects KOSDAQ biotech to receive renewed attention after the main earnings season and frames it as a longer holding rather than a quick trade.
HIGH
23:45
Jan 02
Jan 02
Buy Korean biotech weakness for February.
Biotech typically underperforms during earnings season and around JP Morgan Healthcare, but the sector has already corrected and many biotech companies are becoming profitable. He remains constructive medium-term, holds a core biotech position, bought significantly since October/November, and expects relative strength after January, likely from February onward; biotech may not lag semiconductors and could even outperform over the medium term.
HIGH
About KOSDAQ biotech sector Investor Commentary
Across the available history and selected sources, Buzzberg tracks KOSDAQ biotech sector across 2 sources: 7 bullish vs 0 bearish calls from 8 authors. Historical directional balance: 58% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 12 total trade ideas tracked. Latest voices: Jeong Tae-geun, Yeom Seung-hwan, So Hyeon-cheol.